Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389054 | PMC |
| http://dx.doi.org/10.32481/djph.2016.04.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Is elimination of cervical cancer in sight in England?
Prev Med
January 2025
Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
Objective: The age-standardised rate of cervical cancer is 8.5 per 100,000 in England, double the WHO "elimination" goal of 4.0 per 100,000, despite England being close to the target coverage for both HPV vaccination and cervical screening.
View Article and Find Full Text PDFCervical cancer incidence and trends among women aged 15-29 years by county-level economic status and rurality - United States, 2007-2020.
Cancer Epidemiol
December 2024
Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Introduction: Variations in cervical cancer incidence rates and trends have been reported by sociodemographic characteristics. However, research on economic characteristics is limited especially among younger women in the United States.
Methods: We analyzed United States Cancer Statistics data to examine age-standardized cervical cancer incidence rates among women aged 15-29 years during 2007-2020.
Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Cervical Cancer Patients Undergoing Definitive Chemoradiation.
Clin Cancer Res
December 2024
MD Anderson, Houston, Texas, United States.
Purpose: The human papillomavirus (HPV) is a significant cause of cervical cancer. We hypothesized that detecting viral cell-free HPV DNA (cfDNA) before, during, and after chemoradiation (chemoRT) could provide insights into disease extent, clinical staging, and treatment response.
Experimental Design: Sixty-six patients with locally advanced cervical cancer were enrolled between 2017 and 2023.
Impact of circulating tumor human papillomavirus DNA kinetics on disease outcomes in HPV-associated oropharyngeal cancer.
Int J Cancer
December 2024
Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Circulating tumor tissue modified (TTMV)-HPV DNA has emerged as a promising biomarker in human papillomavirus associated oropharyngeal squamous cell carcinoma (HPV-OPSCC). The objective of this study was to assess ctHPVDNA TTMV clearance kinetics during RT and its relationship with progression in HPV-OPSCC. We identified 80 non-metastatic HPV-OPSCC patients with 366 TTMV samples who underwent prospective plasma TTMV testing before, during and after curative intent RT or CRT between June 2021 and February 2023.
View Article and Find Full Text PDFClinical, histopathological and immunohistochemical analysis of vulvar squamous cell carcinoma.
Rev Bras Ginecol Obstet
December 2024
Universidade Federal de Ciências da Saúde de Porto Alegre Porto AlegreRS Brazil Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.
Article Synopsis
- The study investigated the correlation between immunohistochemical markers (p16, p53, PDL1) and clinical characteristics in vulvar squamous cell carcinoma (SCC) samples from patients.
- The sample consisted of 41 patients with a mean age of 72.1 years, revealing that p16 was positive in 24.4% and PDL1 in 17.1% of samples, while p53 showed varied expression levels.
- Results indicated that p16 positivity was linked to shallower invasion depths, whereas abnormal p53 levels correlated with deeper invasion; PDL1 expression suggested a relationship with increased inflammatory cell presence in the tumors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!